Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD

Shih H. Lin, Yuh Feng Lin, Shi W. Kuo, Yu Juei Hsu, Yi J. Hung

研究成果: 雜誌貢獻文章

47 引文 (Scopus)

摘要

Background: Insulin resistance, a strong risk factor for atherosclerotic vascular disease, is present in uremic patients without diabetes on continuous ambulatory peritoneal dialysis (CAPD) therapy. Amelioration of insulin resistance may reduce associated long-term cardiovascular complications. The aim of the study is to investigate the effects of rosiglitazone (ROS), an insulin sensitizer, on glucose metabolism in CAPD patients without diabetes. Methods: Fifteen uremic patients without diabetes on CAPD therapy were enrolled. All were administered ROS, 4 mg/d, for 12 weeks. A control group consisted of 15 age- and sex-matched healthy subjects. Oral glucose tolerance test (OGTT) results, fasting glucose and insulin levels, related blood biochemistry results, and C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels were determined before initiation and at 4 and 12 weeks of therapy. Insulin resistance was evaluated using the homeostasis model assessment method (HOMA-IR). A whole-body insulin sensitivity index (ISI) and insulinogenic index for insulin production were calculated from OGTT results. Results: CAPD patients showed significantly greater HOMA-IR and glucose intolerance compared with healthy controls. After 4 and 12 weeks of ROS therapy, there were no significant changes in body weight, blood pressure, dialysis adequacy, hemoglobin level, hemoglobin A1c level, liver function, lipid profile, or intact parathyroid hormone, CRP, IL-6, or TNF-α levels. There was a significant decrease in HOMA-IR (3.2 ± 0.6, 2.2 ± 0.4, and 2.1 ± 0.4; P <0.05). During the OGTT, there was a significant decrease in the area under the glucose curve and a significant increase in ISI (3.5 ± 0.4, 5.0 ± 0.7, and 5.3 ± 0.7; P <0.05), but no significant change in insulinogenic index. Conclusion: ROS improved insulin resistance in CAPD patients without diabetes. Whether long-term use of ROS reduces cardiovascular risk needs further study.

原文英語
頁(從 - 到)774-780
頁數7
期刊American Journal of Kidney Diseases
42
發行號4
DOIs
出版狀態已發佈 - 十月 1 2003
對外發佈Yes

指紋

rosiglitazone
Continuous Ambulatory Peritoneal Dialysis
Insulin Resistance
Glucose
Glucose Tolerance Test
Insulin
C-Reactive Protein
Interleukin-6
Hemoglobins
Tumor Necrosis Factor-alpha
Body Weight Changes
Glucose Intolerance
Therapeutics
Parathyroid Hormone
Vascular Diseases
Biochemistry
Area Under Curve
Dialysis
Fasting
Healthy Volunteers

ASJC Scopus subject areas

  • Nephrology

引用此文

Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. / Lin, Shih H.; Lin, Yuh Feng; Kuo, Shi W.; Hsu, Yu Juei; Hung, Yi J.

於: American Journal of Kidney Diseases, 卷 42, 編號 4, 01.10.2003, p. 774-780.

研究成果: 雜誌貢獻文章

Lin, Shih H. ; Lin, Yuh Feng ; Kuo, Shi W. ; Hsu, Yu Juei ; Hung, Yi J. / Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. 於: American Journal of Kidney Diseases. 2003 ; 卷 42, 編號 4. 頁 774-780.
@article{c510f53245f04bef85856cadb917a48d,
title = "Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD",
abstract = "Background: Insulin resistance, a strong risk factor for atherosclerotic vascular disease, is present in uremic patients without diabetes on continuous ambulatory peritoneal dialysis (CAPD) therapy. Amelioration of insulin resistance may reduce associated long-term cardiovascular complications. The aim of the study is to investigate the effects of rosiglitazone (ROS), an insulin sensitizer, on glucose metabolism in CAPD patients without diabetes. Methods: Fifteen uremic patients without diabetes on CAPD therapy were enrolled. All were administered ROS, 4 mg/d, for 12 weeks. A control group consisted of 15 age- and sex-matched healthy subjects. Oral glucose tolerance test (OGTT) results, fasting glucose and insulin levels, related blood biochemistry results, and C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels were determined before initiation and at 4 and 12 weeks of therapy. Insulin resistance was evaluated using the homeostasis model assessment method (HOMA-IR). A whole-body insulin sensitivity index (ISI) and insulinogenic index for insulin production were calculated from OGTT results. Results: CAPD patients showed significantly greater HOMA-IR and glucose intolerance compared with healthy controls. After 4 and 12 weeks of ROS therapy, there were no significant changes in body weight, blood pressure, dialysis adequacy, hemoglobin level, hemoglobin A1c level, liver function, lipid profile, or intact parathyroid hormone, CRP, IL-6, or TNF-α levels. There was a significant decrease in HOMA-IR (3.2 ± 0.6, 2.2 ± 0.4, and 2.1 ± 0.4; P <0.05). During the OGTT, there was a significant decrease in the area under the glucose curve and a significant increase in ISI (3.5 ± 0.4, 5.0 ± 0.7, and 5.3 ± 0.7; P <0.05), but no significant change in insulinogenic index. Conclusion: ROS improved insulin resistance in CAPD patients without diabetes. Whether long-term use of ROS reduces cardiovascular risk needs further study.",
keywords = "Continuous ambulatory peritoneal dialysis (CAPD), Glucose tolerance, Insulin resistance, Rosiglitazone (ROS), Uremia",
author = "Lin, {Shih H.} and Lin, {Yuh Feng} and Kuo, {Shi W.} and Hsu, {Yu Juei} and Hung, {Yi J.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0272-6386(03)00844-8",
language = "English",
volume = "42",
pages = "774--780",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD

AU - Lin, Shih H.

AU - Lin, Yuh Feng

AU - Kuo, Shi W.

AU - Hsu, Yu Juei

AU - Hung, Yi J.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Background: Insulin resistance, a strong risk factor for atherosclerotic vascular disease, is present in uremic patients without diabetes on continuous ambulatory peritoneal dialysis (CAPD) therapy. Amelioration of insulin resistance may reduce associated long-term cardiovascular complications. The aim of the study is to investigate the effects of rosiglitazone (ROS), an insulin sensitizer, on glucose metabolism in CAPD patients without diabetes. Methods: Fifteen uremic patients without diabetes on CAPD therapy were enrolled. All were administered ROS, 4 mg/d, for 12 weeks. A control group consisted of 15 age- and sex-matched healthy subjects. Oral glucose tolerance test (OGTT) results, fasting glucose and insulin levels, related blood biochemistry results, and C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels were determined before initiation and at 4 and 12 weeks of therapy. Insulin resistance was evaluated using the homeostasis model assessment method (HOMA-IR). A whole-body insulin sensitivity index (ISI) and insulinogenic index for insulin production were calculated from OGTT results. Results: CAPD patients showed significantly greater HOMA-IR and glucose intolerance compared with healthy controls. After 4 and 12 weeks of ROS therapy, there were no significant changes in body weight, blood pressure, dialysis adequacy, hemoglobin level, hemoglobin A1c level, liver function, lipid profile, or intact parathyroid hormone, CRP, IL-6, or TNF-α levels. There was a significant decrease in HOMA-IR (3.2 ± 0.6, 2.2 ± 0.4, and 2.1 ± 0.4; P <0.05). During the OGTT, there was a significant decrease in the area under the glucose curve and a significant increase in ISI (3.5 ± 0.4, 5.0 ± 0.7, and 5.3 ± 0.7; P <0.05), but no significant change in insulinogenic index. Conclusion: ROS improved insulin resistance in CAPD patients without diabetes. Whether long-term use of ROS reduces cardiovascular risk needs further study.

AB - Background: Insulin resistance, a strong risk factor for atherosclerotic vascular disease, is present in uremic patients without diabetes on continuous ambulatory peritoneal dialysis (CAPD) therapy. Amelioration of insulin resistance may reduce associated long-term cardiovascular complications. The aim of the study is to investigate the effects of rosiglitazone (ROS), an insulin sensitizer, on glucose metabolism in CAPD patients without diabetes. Methods: Fifteen uremic patients without diabetes on CAPD therapy were enrolled. All were administered ROS, 4 mg/d, for 12 weeks. A control group consisted of 15 age- and sex-matched healthy subjects. Oral glucose tolerance test (OGTT) results, fasting glucose and insulin levels, related blood biochemistry results, and C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels were determined before initiation and at 4 and 12 weeks of therapy. Insulin resistance was evaluated using the homeostasis model assessment method (HOMA-IR). A whole-body insulin sensitivity index (ISI) and insulinogenic index for insulin production were calculated from OGTT results. Results: CAPD patients showed significantly greater HOMA-IR and glucose intolerance compared with healthy controls. After 4 and 12 weeks of ROS therapy, there were no significant changes in body weight, blood pressure, dialysis adequacy, hemoglobin level, hemoglobin A1c level, liver function, lipid profile, or intact parathyroid hormone, CRP, IL-6, or TNF-α levels. There was a significant decrease in HOMA-IR (3.2 ± 0.6, 2.2 ± 0.4, and 2.1 ± 0.4; P <0.05). During the OGTT, there was a significant decrease in the area under the glucose curve and a significant increase in ISI (3.5 ± 0.4, 5.0 ± 0.7, and 5.3 ± 0.7; P <0.05), but no significant change in insulinogenic index. Conclusion: ROS improved insulin resistance in CAPD patients without diabetes. Whether long-term use of ROS reduces cardiovascular risk needs further study.

KW - Continuous ambulatory peritoneal dialysis (CAPD)

KW - Glucose tolerance

KW - Insulin resistance

KW - Rosiglitazone (ROS)

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=0141620204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141620204&partnerID=8YFLogxK

U2 - 10.1016/S0272-6386(03)00844-8

DO - 10.1016/S0272-6386(03)00844-8

M3 - Article

C2 - 14520628

AN - SCOPUS:0141620204

VL - 42

SP - 774

EP - 780

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4

ER -